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THE effect of selective PDE-I (vinpocetine), PDE-III (mil-
rinone, CI-930), PDE-IV (rolipram, nitroquazone), and
PDE-V (zaprinast) isozyme inhibitors on TNF-t and
IL-I production from LPS stimulated human monocytes
was investigated. The PDE-IV inhibitors caused a
concentration dependent inhibition of TNF-0 production,
but only partially inhibited IL-I at high concentrations.
High concentrations of the PDE-III inhibitors weakly
inhibited TNF-t, but had no effect on IL-lfl production.
PDE-V inhibition was associated with an augmentation
of cytokine secretion. Studies with combinations of PDE
isozyme inhibitors indicated that PDE-III and PDE-V
inhibitors modulate rolipram’s suppression of TNF-
production in an additive manner. These data confirm that
TNF- and IL-I production from LPS stimulated human
monocytes are differentially regulated, and suggest that
PDE-IV inhibitors have the potential to suppress TNF-
levels in man.
Key words: cAMP, Cytokine, Endotoxin, Human monocytes,
Interleukin lfl, Phosphodiesterase inhibitors, Tumour necrosis
factor-0.
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Introduction
Activation of monocytes results in the secretion
of numerous cytokines, including 11-1 and tumour
necrosis factor o (TNF-o), which play key roles in
regulation of the immune system. 1’2 However,
unregulated overproduction of these cytokines has
been cited as a major factor in the development of
septic shock, rheumatoid arthritis and inflammatory
lesions. 1’2 Thus, the production of these cytokines
must be tightly controlled by numerous mechan-
isms. Macrophage activation induces a rise in the
rate of transcription for IL-1 and TNF-o mRNA
and a concurrent increase in the stability1’3 and
translational efficiency of TNF-o mRNA. The
precursors of the cytokines are enzymatically
cleaved, and TNF-o and IL-lfl are released into the
interstitial spaces or blood. 1’2 Typically, monocyte
activation is associated with a 200--3000 fold and
150-1000 fold increase in TNF-o and IL-lfl
production, respectively. Although endotoxin in-
duces monocytes to secrete both IL-lfl and TNF-o,
the production of these cytokines has been shown
to be differentially regulated.
3-5 For example,
IL-1, but not TNF-, production by endotoxin
induced monocytes can be selectively decreased by
a calmodulin dependent kinase inhibitor, H7.
Cellular activation is often accompanied by changes
in the intracellular levels of cyclic nucleotides, and
phosphodiesterases, by metabolizing the intra-
cellular cyclic nucleotides, play a major role
in modulating their intracellular concentrations.
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The nonspecific phosphodiesterase (PDE) in-
hibitors, theophylline, 3-isobutyl-l-methylxanthine
(IBMX), and pentoxifylline, selectively decrease
TNF-o mRNA steady state levels and TNF-
production from endotoxin-stimulated murine and
human monocytes.
(’-8 However, the effect of agents
which augment intracellular levels of cAMP on
IL-lfl production from LPS induced macrophages
varies depending on the species, stimulus, and
culture conditions;
2 results ranging from stimula-
tion to no effects to inhibition
-2 have been
reported.
There are five distinct families of phosphodiester-
ase (PDE) isoenzymes which differ in their cyclic
nucleotide substrate specificities and tissue distribu-
tion.3’4 Selective inhibitors for PDE-I, PDE-III,
PDE-IV and PDE-V have been identified, although
the selective inhibitors may display some inhibitory
effect on other PDE isoenzymes at higher
concentrations.s PDE-IV has been isolated from
human monocytes,
16 and PDE activity was also
detected in peaks eluting in buffers for PDE-I and
PDE-V isolation from routine macrophages.
This study was undertaken to investigate the role
of cAMP, cGMP and PDE isoenzymes in
regulation of monocyte cytokine production. The
effect of selective inhibitors of the PDE-I, PDE-III,
PDE-IV and PDE-V isotypes on intracellular and
.secreted TNF-o and IL-lfi production from
endotoxin stimulated human monocytes was
analysed. Interactions between the regulation
exerted by PDE isoenzymes were investigated in
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combination studies with PDE-I, PDE-III,
PDE-V inhibitors and PDE-IV inhibitor.
or
Materials and Methods
Reagents: CI-930 (Parke Davis Pharmaceutical
Research, Ann Arbor, MI), milrinone, (Sterling
Winthrop Research Institute, Rennsalear, NY),
rolipram (Schering AG, Berlin, Germany), ni-
traquazone (Troponwerke, Nordrhein-Westfalen,
Germany), and zaprinast (May and Baker, Essex,
UK) were generously provided by their respective
manufacturers. Vinpocetine was made by Wyeth-
Ayerst Research, Princeton, NJ. Dexamethasone
was purchased from Sigma (St Louis, MO) and
stored at 4C. Each drug was dissolved in 100%
ethanol or DMSO to yield a final concentration of
10 mM. The stocks were diluted just before use
with culture media, consisting of RPMI 1640
(Gibco, Gaithersburg, MD) supplemented with 5%
foetal calf serum (FCS; Hyclone, Logan, UT),
25 mM HEPES, 2 mM L-glutamine, 100/,g Na-
pyruvate, 100 U/ml penicillin, and 100 #g/ml
streptomycin (RPMI 1640-5% FCS). Three different
types of lipopolysaccharide (LPS), 0111 :B4, 055 :B5,
and 026:B6 were purchased from List Biologicals
(Campbell, CA), Sigma (St Louis, MO) and Difco
(Detroit, MI), respectively for optimization of the
assay. LPS was dissolved in Ca2+, Mgi+-free
Dulbecco’s phosphate buffer saline (PBS) (Gibco)
to produce a stock containing 5 mg/ml, diluted to
1 mg/ml in PBS, aliquoted and then stored frozen
at -20C. LPS was thawed and diluted with RPMI
1640-5% FCS as needed.
Human monocyte assay: Human mononuclear cells were
isolated by Ficoll hypaque density centrifugation
(specific gravity 1.077) from Leukapaks obtained
from healthy Caucasian males. The bully coat layer
was washed three times in RPMI 1640 and
enumerated. Human mononuclear cells were plated
into 24-well plates (106 cells in l ml RPMI
1640-5% FCS/well) or flat-bottom microtitre plates
(3.76 10 cells in 100/zl/ well) and incubated at
37C in 5% CO2 in a humidified atmosphere for
45 min. The wells were rinsed three times to remove
non-adherent cells. The quantity of baseline and
LPS stimulated cytokine production was measured
from cells incubated in the absence or presence of
0.1 ng LPS (0111 :B4 subtype) per ml, respectively,
for 16-24 h at 37C in 5% CO2 in a humidified
atmosphere. To assess the effect of drugs, varying
concentrations ofcompounds or vehicle were added
to the cells just prior to their incubation with 100
pg LPS/ml in RPMI 1640-5% FCS as above. All
tests were performed in duplicate. To measure the
concentration of secreted and cell associated IL-lfl
and TNF-0, supernatants were harvested. To assess
cell associated cytokine levels, RPMI 1640 (0.3 ml)
was added to the cells. Samples were frozen at
-80C and stored. Cell lysates were prepared by
thawing plates, scraping cells from the well, adding
0.2 ml RPMI 1640, scraping remaining cells from
the wells, and pooling samples followed by two
additional freeze-thaw cycles.
17 The cell lysate was
diluted two-fold with RPMI 1640 containing 10%
FCS to yield a final volume of 1 ml. It should be
noted that the effect of nitraquazone on monokine
secretion was assessed in a set of experiments
(n 3) in which samples were not processed for
analysis of cell associated monokine levels.
The viability of the LPS stimulated cells in the
presence or absence of a test compound was
assessed in the microtitre plates following a 16-24 h
incubation at 37C in 5% CO2 using the previously
described assay based on the metabolic reduction
of 3-(4,5-dimethyl-thiazol-2yl)-2,5 diphenyl tetra-
zolium bromide (MTT).
18 None of the PDE
inhibitors tested at the same concentrations
decreased the viability of the monocytes.
IL- fl and TNF- assays: The concentrations of IL-lfl
and TNF-0 in the supernatants and cell lysates were
measured in duplicate using ELISA kits (Cistron,
Pine Brook, NJ). The standards, supernatants and
cell lysates were diluted with RPMI 1640-5% FCS
just before use. After the addition of the samples
and standards to the appropriate wells, the plates
were incubated at 37C overnight in a humidified
atmosphere containing 5% CO2. The plates were
then processed according to the manufacturer’s
instructions. However, the analysis was performed
as listed below. The standard curve was fit to the
following equation:
OD C + (D C)/
[1 + Exp (--(A + B* Lgt (drug conc)))]
Where OD was set to the optical density, C the
estimated minimum, D the estimated maximum and
A and B are derived as parameters of intercept and
slope, respectively.
The concentration of cytokine was calculated by
inverse prediction. Percent inhibition was calcu-
lated as follows:
% Inhibition (1 [test]- baseline x 100
stimulated- baselineJ
The ICs0 value, defined as 50% inhibition of the
stimulated control response was determined by
inverse prediction of the following equation:
Concentration C 4- D
Where D equals the cytokine concentration in
the stimulated control less that of the baseline
control.
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Statistics: To determine whether the individual PDE
inhibitors significantly blocked TNF-0 and IL-lfl
production and/or secretion, an analysis of variance
for a randomized block design (using each donor
as a block) was performed.
19 This included all treat-
ments where a single PDE inhibitor was given.
Similarly, to assess whether the PDE-I, PDE-1II
and PDE-V inhibitors could modulate the inhibi-
tion of TNF- by rolipram alone, a similar analysis
was performed. A separate analysis was performed
for each combination, and all treatment groups
including either drug alone or in combination were
included. A t-statistic taking into account the
within- and between-donor variation was used to
test whether the percent inhibition observed was
significantly different from zero. Degrees of
freedom were approximated by Satterwaite’s
formula.
2 Interaction between drugs was tested by
estimating the expected inhibition for the combina-
tion based on the inhibition for the individual PDE
inhibitors and testing whether this was significantly
different from the observed inhibition for the
combination. Pairwise comparisons using the least
significant difference method were performed to test
whether the combination was better than either
drug alone.
Wasik and Beller
21 have observed that the
inhibitory effect of compounds on cytokine
production may be minimized by overstimulating
the monocytes. As an initial step, the quantity of
endotoxin was titrated to determine the concentra-
tion required to stimulate near maximal release of
IL-lfl and TNF- from human monocytes. As
shown in Fig. 1, 0.1 ng/ml of lipopolysaccharide
(LPS) induced near maximal release of both IL-lfl
and TNF-, regardless of the LPS subtype.
Therefore, 0.1 ng/ml LPS (subtype 0111 :BB4) was
used to assess the effect of drugs on cytokine release.
The quantity of IL-lfl and TNF-0 secreted by
LPS stimulated monocytes increased by 100 to
1000-fold over the baseline level of 4-13 pg/ml and
5-23 pg/ml, respectively (data not shown). The cell
associated TNF-0 was less than 10% of the total
produced, whereas the cell associated IL-lfl ranged
from 33.8% to 61.8% of the total produced. The
level of TNF- and IL-lfl elicited by LPS
stimulation ofhuman monocytes varied from donor
to donor, in agreement with prior reports. 22’23
Effect of PDE inhibitors on monokine release: TNF-0
secretion was significantly suppressed by the
PDE-IV inhibitors, rolipram and nitraquazone, in
a concentration dependent manner (Fig. 2A), with
maximal inhibition of approximately 80% noted at
10#M. The ICs0 values of rolipram and ni-
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FIG. 1. Concentration response curve of lipopolysaccharide on cytokine
production from human monocytes isolated from one donor. Similar
response curves were observed with other donors. Effect of various
concentrations of LPS on TNF-z secretion (A) and on IL-lfl secretion
(B) from stimulated human monocytes.
traquazone were 0.38 #M and 0.23/M, respec-
tively. The PDE-III inhibitors, CI 930 and
milrinone, at 10 #M only suppressed TNF-a with
a maximal inhibition of 24% and 13%, respectively.
Although the PDE-I inhibitor, vinpocetine, did not
affect TNF<z production, the PDE-V inhibitor,
zaprinast, at 10 #M modestly but significantly
augmented the TNF- secretion. In agreement with
previous reports,
23 dexamethasone exhibited an ICs0
of 0.01 #M for these same donors, with 90%
inhibition of TNF- noted at the highest
concentrations used.
Rolipram at 10 #M and nitraquazone at 1 and
10#M suppressed IL-lfl secretion from LPS
stimulated human monocytes (n 13 and n 3,
respectively), although there was much variability
in the sensitivity of the response to these drugs (Fig.
2B). For example, IL-lfl inhibition at 10#M
rolipram or nitraquazone ranged from -43% to
53% and 14% to 57%, respectively. Vinpocetine, CI
930 and milrinone did not have a significant eect
on IL-lfl secretion. In contrast, zaprinast, a PDE-V
inhibitor, significantly augmented the release of
IL-lfi from LPS stimulated human monocytes.
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FIG. 2. The effect of dexamethasone and PDE inhibitors on TNF- or
IL-1 fl secretion from LPS induced human monocytes. The mean effect -I-
standard error of these drugs on TNF- (A) and on IL-lfl (B) secretion
(n >_ 3) is plotted. Values were significantly different from the control at
the p 0.05 (’) or p 0.01 (") levels.
Zaprinast was ten times more potent in augmenting
IL-lfl secretion than TNF-0 secretion. Dexa-
methasone suppressed IL-lfl production (ICs0
0.02 #M) as expected8’23 (Fig. 3B).
The PDE inhibitors tested at the above
concentrations did not decrease the viability of the
cells as determined by the MTT assay. Therefore,
the effect on cytokine production was not due to
cytotoxicity.
Combination studies: In order to determine whether the
PDE-I, PDE-III, PDE-IV or PDE-V inhibitors
exerted their effects on TNF-0 in an additive,
synergistic or antagonistic manner, the effect of
combinations of submaximal levels of rolipram (0.1
and 0.3/M) with 3 and 10M concentrations of
vinpocetine, CI 930, milrinone, and zaprinast was
evaluated. As shown in Fig. 3, rolipram’s inhibition
of TNF-0 release was increased by the presence of
CI 930 (3 #m and 10/zM) and milrinone (10 #M)
in an additive manner. Vinpocetine had no effect
on rolipram’s suppression of TNF-0. Zaprinast
(10/M) alone augmented TNF-0 and in combina-
tion with rolipram decreased rolipram’s inhibition
of TNF-0 secretion in an additive manner.
Cell associated cytokines: Cell associated cytokines were
quantitated in order to probe the effect of the
selective PDE inhibitors on the intracellular
cytokine concentrations. Similar to their effects on
secretion of TNF-0, both CI 930 and rolipram also
decreased the level of TNF-0 which was cell
associated (Fig. 4A). Although zaprinast signi-
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FIG. 3. The effect of PDE-I, III, and V inhibitors on rolipram’s suppressive effect on TNF-0 secretion. TNF- in the absence (0#M rolipram) or
presence of (0.1 or 0.3/,M rolipram) the PDE-IV inhibitor is depicted by the curve labelled ’control’ (A). The effect of other PDE isozyme
inhibitors assessed at concentrations of 3#M (A) or 10/M (B) on the effect of rolipram’s inhibition of TNF- secretion is plotted. Vinpocetine
(O), Cl 930 (V), milrinone (O), or zaprinast (’) were the PDE isozyme inhibitors employed.
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FIG. 4. The effect of dexamethasone and PDE inhibitors on production
of cell associated TNF- or IL-I from LPS induced human monocytes.
The mean effect standard error of these drugs on cell associated TNF-
(A) and IL-lfl (B) (n 2 2). Values were significantly different from the
control at the p 0.05 (’) or p 0.01 (") levels.
ficantly augmented secreted TNF-z production
(p 0.004), the apparent increase in cell associated
TNF-0 by zaprinast was not significant (p 0.2).
Similar to zaprinast’s effects on IL-lfi secretion,
the level of cell associated IL-lfi was significantly
augmented by zaprinast (Fig. 4B). Although
vinpocetine, CI 930, and milrinone did not affect
the intracellular levels of IL-1/, 10/M rolipram
significantly increased the concentration of cell
associated IL-lfl. This increase in cell associated
IL-lfl occurred at rolipram concentrations similar
to those which inhibited IL-1/ secretion. Dexa-
methasone significantly suppressed cell associated
TNF-0 and IL-lfl (ICs0 =0.02 and 0.01 #M,
respectively).
Discussion
Agents which regulate intracellular cyclic nucleo-
tide levels such as dibutryl cAMP (dbcAMP),
prostaglandin E2 (PGE2) and phosphodiesterase
inhibitors can modulate macrophage functions.
Superoxide generation from guinea pig peritoneal
macrophages was inhibited by rolipram and
Ro-20-1724, two PDE-IV inhibitors, but not by
SKF 94120, a PDE-III inhibitor.24 Human alveolar
macrophage activation was modestly suppressed by
forskolin; Ro-20-1724 had no effect.
25 Agents which
elevate cAMP levels, such as dbcAMP, isoproter-
enol, and nonselective PDE inhibitors (e.g.
pentoxifylline, IBMX, and theophylline), sup-
pressed the production ofTNF- from LPS induced
monocytes and macrophages. -8’11 The present
studies showed that selective PDE isoenzyme
inhibitors can differentially effect the production of
TNF-0 and IL-lfl from LPS induced human
monocytes. Rolipram and nitraquazone, selective
inhibitors of PDE-IV, suppressed production of
secreted TNF-z with a maximal inhibition of
approximately 80% (Fig. 3A). CI 930 and milrinone
at concentrations of 3 and 10#M modestly
depressed TNF-0 secretion. Although CI 930 and
milrinone can inhibit PDE-IV enzymatic activity at
concentrations greater than 100 #M and 10 #M,
respectively, ls’26 the inhibition of TNF-0 produc-
tion by CI 930 occurred at lower concentrations.
Thus, the effect of at least CI 930 is most likely
caused by suppression of inherent PDE-III activity
in the monocytes. The observation that combina-
tions of these PDE-III inhibitors and rolipram
resulted in additive suppression of TNF-0 produc-
tion are consistent with the expectation that these
agents mediate their effect via the same mechanism
(elevation of cAMP levels).
In contrast, zaprinast, a PDE-V inhibitor that is
expected to regulate cGMP levels, modestly but
significantly increased secreted TNF-0 at 10 #M, in
agreement with reports of other agents which
elevate intracellular cGMP levels (sodium ni-
troprusside and exogenous cGMP) and which
stimulate TNF-0 production.
6 The observation that
the combination of zaprinast with rolipram
decreased the TNF-0 inhibition observed with
rolipram alone in an additive manner is consistent
with opposing roles for PDE-V/cGMP and
PDE-IV/cAMP in TNF-0 secretion by endotoxin
stimulated monocytes.
TNF-0 production from activated macrophages
is increased 100 to 5000-fold by a combination of
elevated transcription rate, increased mRNA
stability and improved translational ediciency.
Since cell associated as well as secreted TNF-0 levels
were inhibited by rolipram and CI 930, these drugs
probably do not inhibit secretion by blocking
precursor processing. The nonspecific PDE in-
hibitors, pentoxifylline and IBMX, have been
shown to reduce steady state levels of mRNA and
suppress TNF-0 production by LPS stimulated
monocytes and macrophages. Elevation of in-
tracellular cAMP levels in LPS stimulated murine
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macrophages by dbcAMP is also reported to
suppress TNF-o production, lower the transcrip-
tion rate and decrease steady state levels of
mRNA. 8’11 Thus, one likely mechanism by which
PDE-I11 and PDE-IV inhibitors may regulate
TNF-o is by decreasing the steady state level of
TNF-o mRNA in the cell.
The effect of cAMP modulating agents on IL-1//
production from LPS activated monocytes varies
with the culture conditions, type of stimulus and
species.
2 Kassis et al.
9 observed that agents which
elevate cAMP stimulate IL-lfl production. Endres
et al.
8 have observed no effect on total IL-lfl protein
or mRNA levels in LPS stimulated monocytes or
macrophages in the presence of agents which
elevated cAMP levels including nonspecific PDE
inhibitors. In contrast, Brandwein,
27 Hurme,
12 and
Knudsen and colleagues
1 reported that concurrent
treatment of LPS induced macrophages with cAMP
elevating agents result in a modest decrease in
secretion of IL-lfl. No effect on IL-I mRNA
steady state levels is observed with treatment with
agents which elevate cAMP levels.
10-12 In the
present studies, rolipram and nitraquazone at high
concentrations did significantly decrease IL-1//
secretion, in agreement with the studies of
Knudsen, Hurme and Brandwein. 1’12’27 Since
rolipram increased the quantity of cell associated
IL-1/ (nitraquazone was not tested), while it
decreased secreted IL-lfl, this data supports the
interesting suggestion that PDE-IV may play a role
in modulating IL-lfl release from the cell.
1 This
action by rolipram may help to account for some
of the differences between previous reports which
assessed the effects on secreted vs. total IL-lfl
production. Secondly, variability of sensitivity of
IL-lfl production to PDE-IV inhibitors between
donor monocyte preparations may also account for
some differences.
Disparate results are observed with cGMP
elevating agents on IL-lfl secretion where SIN-1
treatment inhibits IL-lfl, dibutryl cGMP has no
effect
12 and in the present study, zaprinast increased
IL-1/ secretion. These disparities may have arisen
due to different levels of stimulation and/or culture
conditions. However, under the same conditions,
the observations that PDE-IV and PDE-V
inhibitors exerted opposite effects on IL-1// and
TNF-o secretion raise the possibility that cAMP and
cGMP may affect endotoxin induced cytokine
secretion in an opposing manner.
The suppressive effect of selective PDE-IV
inhibitors on TNF-o suggests that these and similar
compounds may be useful in the prophylactic
and/or therapeutic treatment of pathologies involv-
ing overproduction of TNF-o. Since anti-TNF-
reagents have been reported to decrease symptoms
in animal models of septic shock, experimental
allergic encephalitis, and collagen induced arthritis,
PDE-IV inhibitors may have a therapeutic benefit
in diseases such as arthritis, septic shock, and
multiple sclerosis. PDE-IV inhibitors have been
suggested also to be of potential benefit in the
treatment of asthma, based upon their significant
bronchodilatory and anti-inflammatory activi-
ties. 14’28 Although the role of TNF-o in asthma has
not been clearly established, a recent report
suggested that increases in bronchoalveolar lavage
TNF-o levels are associated with exacerbations of
asthma.
29 Furthermore, TNF- was reported to
stimulate eosinophil oxidant production and
toxicity towards human endothelium.
3 Thus, it
may also be suggested that the anti-TNF<z activities
of PDE-IV inhibitors will contribute to their
anti-asthma profiles. Further experiments will be
needed to explore this possibility.
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